{"id":319,"date":"2019-01-17T08:32:21","date_gmt":"2019-01-17T08:32:21","guid":{"rendered":"http:\/\/206.71.52.87\/~newwebproject\/?page_id=319"},"modified":"2023-05-10T09:02:52","modified_gmt":"2023-05-10T09:02:52","slug":"trial-design","status":"publish","type":"page","link":"https:\/\/cdsatoolkit.thsti.in\/?page_id=319","title":{"rendered":"Trial Design"},"content":{"rendered":"<div class=\"flex_column av_one_half  flex_column_div first  \" style='padding:0px 15px 0px 2px ; border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><div class=\"dfr1\"><strong>Clinical Trials Toolkit &#8211; India<\/strong><\/div>\n<\/div><\/section><\/div>\n<div class=\"flex_column av_one_half  flex_column_div   \" style='padding:0px 0px 10px 0px ; border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><div class=\"dfr\" style=\"text-align: right;\"><strong><strong>You are in: Home \/ Routemap \/ <\/strong>Trial Design<\/strong><\/div>\n<\/div><\/section><\/div>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='sdew' class='avia-section main_color avia-section-default avia-no-shadow avia-bg-style-scroll   container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  flex_column_div first  \" style='padding:0px 0px 0px 12px ; border-radius:0px; '><div class='avia-button-wrap avia-button-left '><a href='\/?page_id=1075' class='avia-button   avia-icon_select-yes-left-icon avia-color-custom avia-size-small avia-position-left '  style='background-color:#1d66a3; border-color:#1d66a3; color:#ffffff; ' ><span class='avia_button_icon avia_button_icon_left ' aria-hidden='true' data-av_icon='\ue888' data-av_iconfont='entypo-fontello'><\/span><span class='avia_iconbox_title' >Previous<\/span><\/a><\/div><\/div><div class=\"flex_column av_three_fifth  flex_column_div   \" style='padding:0px 0px 0px 0px ; border-radius:0px; '><div style='padding-bottom:10px;' class='av-special-heading av-special-heading-h2  blockquote modern-quote modern-centered   '><h2 class='av-special-heading-tag '  itemprop=\"headline\"  >Trial Design<\/h2><div class='special-heading-border'><div class='special-heading-inner-border' ><\/div><\/div><\/div><\/div><div class=\"flex_column av_one_fifth  flex_column_div   \" style='padding:15px 0px 0px -15px ; border-radius:0px; '><div class='avia-button-wrap avia-button-right '><a href='https:\/\/cdsatoolkit.thsti.in\/?page_id=309' class='avia-button   avia-icon_select-yes-right-icon avia-color-custom avia-size-small avia-position-right '  style='background-color:#1d66a3; border-color:#1d66a3; color:#ffffff; ' ><span class='avia_iconbox_title' >Next<\/span><span class='avia_button_icon avia_button_icon_right' aria-hidden='true' data-av_icon='\ue889' data-av_iconfont='entypo-fontello'><\/span><\/a><\/div><\/div>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='after_section_1' class='main_color av_default_container_wrap container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='lop1' class='avia-section main_color avia-section-default avia-no-shadow avia-bg-style-scroll   container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n<section class=\"avia_codeblock_section  avia_code_block_0\"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_codeblock '  itemprop=\"text\" > [avia_codeblock_placeholder uid=\"0\"] <\/div><\/section>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='after_section_2' class='main_color av_default_container_wrap container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='nbvc' class='avia-section main_color avia-section-large avia-no-shadow avia-bg-style-scroll   container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_two_third  flex_column_div first  \" style='padding:8px 0px 0px 14px ; border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: justify;\">Trial design encompasses all the processes which are essential to ensure successful outcome of the clinical trial. It starts with framing the right research question based on the hypothesis and spans trial methodology and all related processes.<\/p>\n<p style=\"text-align: justify;\">A well-developed proposal and protocol helps identify the critical elements of a trial. It ensures that the necessary practical requirements are in place, adequate funds are requested and facilitates securing necessary regulatory and ethical approvals.<\/p>\n<p>The sections below are key to successful trial design:<\/p>\n<h4><strong>Hypothesis<\/strong><\/h4>\n<p style=\"text-align: justify;\">A hypothesis provides justification for a clinical trial, and helps establish its direction. It is developed from the main elements of the proposed research \u2013 sampling strategy, intervention (if applicable), comparison and outcome variables. The hypothesis is stated at the beginning, to guide the objectives of the trial. The investigator must adhere to the principles of clinical equipoise. According to this principle, there must exist a genuine uncertainty regarding the comparative therapeutic merits of each proposed arm in a trial.<\/p>\n<p style=\"text-align: justify;\">The hypothesis is based on the primary research question, and must be developed before the start of the trial. It will influence the development of the research objectives and study design; and drive the data collection throughout the study.<\/p>\n<h4><strong>Research Question <\/strong><\/h4>\n<p style=\"text-align: justify;\">Defining a clear and focused research question is crucial. It helps narrow down aims and objective. Furthermore, once defined, the research question helps guide the methodology, sample size calculations, instruments to be used for collection of data and tools for data analyses. Numerous authors and experts have suggested pathways \/ steps to developing a research question, based on area of interest, critical review of the published literature (ideally systematic review), and identifying a well-defined problem.<\/p>\n<p style=\"text-align: justify;\">The researcher may have multiple research questions. However, it is imperative that the primary research question is clearly defined, because it will guide the basis for the hypothesis, aims and objectives. The research question may change or get modified, as the researcher works through the various steps of trial design and literature review. Research questions can be answered through different methodologies:<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\"><strong>Quantitative:<\/strong> These are generally precise, and can be categorised as Descriptive, Comparative or Relationship.<\/li>\n<li><strong>Qualitative:<\/strong> These are generally more flexible and adaptable.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify;\"><strong>Mixed method studies:<\/strong> some researchers choose to develop separate quantitative and qualitative i.e. mixed method questions depending on the type of study being conducted.<\/li>\n<\/ul>\n<h4><strong>Research Objectives<\/strong><\/h4>\n<p style=\"text-align: justify;\">Research objective is a statement on how the clinical trial is going to answer a specific research question. As compared to the aims, these are generally more specific and are directly linked to the research question. The research questions may be divided into two categories:<\/p>\n<ul>\n<li>Primary: likely to be achieved, and directly linked with the hypothesis.<\/li>\n<li>Secondary: incidental objectives.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The research objectives should cover all aspects of the research problem, be specific, follow a logical sequence or order, achievable, based on the available resources and be mutually exclusive of each other. Some typical research objectives could be: exploratory, descriptive, explanatory, predictive or influential. When setting a research question the following criteria may also be applied: <strong>S<\/strong>pecific, <strong>M<\/strong>easurable, <strong>A<\/strong>ppropriate, <strong>R<\/strong>ealistic and <strong>T<\/strong>ime-specific (SMART \u2013 given by Doran in 1981).<\/p>\n<p style=\"text-align: justify;\">The research objectives can also sometimes detail on the outcome measures going to the used, help guide the development of the protocol, study design and influence sample size calculations.<\/p>\n<h4><strong>Trial Design <\/strong><\/h4>\n<p style=\"text-align: justify;\">The effectiveness of an intervention depends on the interpretation of data generated during a trial, and its strength. In other words, the more controlled is the trial, the stronger is the data generated. Considering this, the design and conduct of the trial plays an extremely important role. The following should be kept in mind, while deciding or selecting a trial design:<\/p>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li>ability of the design to answer the primary research question<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"text-align: justify;\">is the trial exploring or studying a new treatment for a condition for which an effective treatment already exists?<\/li>\n<li>is the condition life-threatening or severe?<\/li>\n<li>what is the probability and extent of risk to the participants?<\/li>\n<li>what is the population under study: its size, availability and accessibility<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"text-align: justify;\">how will the data (collected during the present trial) be utilised: to start the new treatment or collection of preliminary data to inform larger trials, etc.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">The choice of design depends on the above-listed factors and others, due to which it is difficult to offer any generalised suggestions. However, one must remember that adherence to the ethical principles, thereby minimising risks and ensuring voluntary consent is of paramount importance. Designs that incorporate these considerations should be considered over others. Randomisation and blinding or masking are techniques that help in risk minimisation. Both these topics are covered in the section of Trial Set-Up of this toolkit.<\/p>\n<p style=\"text-align: justify;\">It is important to note that the regulations and guidelines (in India) might differ depending on the investigational product. It is recommended that the researcher refer these, wherever applicable:<\/p>\n<table width=\"100%\">\n<tbody>\n<tr>\n<td width=\"24%\">New Chemical Entity<\/td>\n<td width=\"75%\">CDSCO\u2019s page on <strong><a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Drugs\/New-Drugs\/\" target=\"_blank\" rel=\"noopener noreferrer\">New Drugs<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"24%\">Bioavailability \/ Bioequivalence Studies<\/td>\n<td width=\"75%\"><a href=\"http:\/\/www.cdsco.nic.in\/writereaddata\/Draft%20guidance%20document%20for%20BA%20BE%20NOC.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">CDSCO (guidance document)<\/a> and page on <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/bioequi_bioavail\/\" target=\"_blank\" rel=\"noopener noreferrer\">BA and BE<\/a>.<\/td>\n<\/tr>\n<tr>\n<td width=\"24%\">Medical Devices<\/td>\n<td width=\"75%\">\n<p style=\"text-align: justify;\">Medical Devices Rules, 2017 and CDSCO\u2019s page on <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Medical-Device-Diagnostics\/Medical-Device-Diagnostics\/\" target=\"_blank\" rel=\"noopener noreferrer\">Medical Devices<\/a>.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"24%\">Stem Cell Research<\/td>\n<td width=\"75%\"><a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/Guidelines_for_stem_cell_research_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">National Guidelines for Stem Cell Research<\/a> (ICMR &amp; DBT, 2017)<\/p>\n<p><a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/faq\/Stem_Cell_Research_in_India_eng.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FAQ&#8217;s on Stem Cell Research in India (ICMR)<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"24%\">AYUSH<\/td>\n<td width=\"75%\"><a href=\"http:\/\/ayush.gov.in\/acts-rules-and-notifications\/good-clinical-practice-guidelines-clinical-trials-asu-medicine\" target=\"_blank\" rel=\"noopener noreferrer\">GCP guidelines <\/a>for clinical trials of ASU Medicine.<\/p>\n<p style=\"text-align: justify;\">The National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 and Chapter IVA (Provisions relating to [Ayurveda, Siddha and Unani] Drugs) in the Drugs and Cosmetic Act, must be referred to as well.<\/p>\n<p style=\"text-align: justify;\">More details are available on CDSCO\u2019s page on <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Traditional_Drugs\/\" target=\"_blank\" rel=\"noopener noreferrer\">Traditional Drugs<\/a>.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"24%\">Diagnostics<\/td>\n<td width=\"75%\">CDSCO\u2019s page on <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Medical-Device-Diagnostics\/Medical-Device-Diagnostics\/\" target=\"_blank\" rel=\"noopener noreferrer\">Diagnostics<\/a>.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4><strong>Regulations and guidelines for clinical research in India<\/strong><\/h4>\n<table style=\"margin-bottom: 0px !important; margin-top: 14px;\" width=\"91%\">\n<tbody>\n<tr>\n<td width=\"100%\">\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/ICMR_Ethical_Guidelines_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) \u2013 ICMR<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"100%\">\n<p style=\"text-align: justify;\"><a href=\"http:\/\/www.cdsco.nic.in\/writereaddata\/2016Drugs%20and%20Cosmetics%20Act%201940%20&amp;%20Rules%201945.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Drugs and Cosmetics Act ,1940 and Rules, 1945 <\/a><a href=\"https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/NewDrugs_CTRules_2019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">(as amended up to the 31st December, 2016)<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"100%\"><a href=\"https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/NewDrugs_CTRules_2019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">New Drugs and Clinical Trial Rules, 2019, G.S.R. 227(E)<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"100%\"><a href=\"http:\/\/www.cdsco.nic.in\/html\/GCP1.html\" target=\"_blank\" rel=\"noopener noreferrer\">Good Clinical Practice guidelines <\/a>\u2013 India (CDSCO)<\/td>\n<\/tr>\n<tr>\n<td width=\"100%\">\n<p style=\"text-align: justify;\"><a href=\"http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Good Clinical Practice guidelines \u2013 ICH<\/a> E6(R2)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"100%\"><a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/National_Ethical_Guidelines_for_BioMedical_Research_Involving_Children_0.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">National Ethical Guidelines for Biomedical Research Involving Children <\/a>(2017) \u2013 ICMR<\/td>\n<\/tr>\n<tr>\n<td width=\"100%\">\n<p style=\"text-align: justify;\">CDSCO\u2019s page on <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Clinical-Trial\/clinical-trials\/\" target=\"_blank\" rel=\"noopener noreferrer\">Clinical Trials<\/a>.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;\" width=\"100%\"><a href=\"http:\/\/www.cdsco.nic.in\/writereaddata\/Scan1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Handbook<\/a> for Applicants and Reviewers of Clinical Trials of New Drugs in India, 2017 (ICMR &amp; CDSCO)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;\" width=\"100%\"><a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/Handbook_on_ICMR_Ethical_Guidelines.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Handbook<\/a> on National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2018) \u2013 ICMR.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">It is also recommended that during discussions on trial design and during protocol development the researcher is aware of the following three parameters that are utilised by the Indian Central Licensing Authority (CDSCO) for <a href=\"http:\/\/www.cdsco.nic.in\/writereaddata\/Office%20Order%20dated%2005_09_2014.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">evaluation<\/a> of clinical trial applications:<\/p>\n<ul>\n<li>Assessment of risk versus benefit to the patient,<\/li>\n<li>Innovation vis-\u00e0-vis existing therapeutic option,<\/li>\n<li>Unmet medical need in the country.<\/li>\n<\/ul>\n<h4><strong>Risk Benefit Analysis <\/strong><\/h4>\n<p style=\"text-align: justify;\">Any favourable or advantageous outcome to the participant (or individual), community or society, due to the research is considered as a benefit. Benefits due to research could be both direct and indirect. The social and scientific value of research should justify the risk. In the context of research, risk is considered as the probability of causing harm or discomfort to the participant or community or the society. These risks could be physical, psychological, economic, social or legal.<\/p>\n<p style=\"text-align: justify;\">The researcher, sponsor and the ethics committee (assessing the research) should aim to minimise these anticipated risks and maximise the benefits, at individual, societal and community levels. The risks and benefits should be assessed in order to ensure a favourable balance between the two.<\/p>\n<p style=\"text-align: justify;\">The risk benefit analysis is a section in the trial design (and the research protocol), that details on the proposed plan for minimising the risks and discomforts of the research. The ethics committee evaluates the merit of the research on the basis of the details in this section, before approving it.<\/p>\n<p style=\"text-align: justify;\">The type of review by the ethics committee is based on the category of risks, as below:<\/p>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"text-align: justify;\"><strong>Less than minimal risk:<\/strong> probability of harm or discomfort is nil or not expected.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"text-align: justify;\"><strong>Minimal risk:<\/strong> probability of harm or discomfort is not greater than that ordinarily encountered in everyday life or routine tests, where the occurrence of serious harm or any adverse event is unlikely.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"text-align: justify;\"><strong>Minor increase over minimal risk or Low risk:<\/strong> increment in probability of harm during the research is only a little more than the minimal. Examples of this are: inclusion of participants who are not capable of giving consent, use of minimally invasive procedures during research, delaying or withholding a proven intervention or standard of care in a control or placebo group during randomized trials, etc.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"text-align: justify;\"><strong>More than minimal risk or High risk:<\/strong> probability of harm or discomfort is more than minimal. Examples of this are: use of invasive procedures (lumbar puncture, lung or liver biopsies, endoscopic procedures) during research, drugs.<\/li>\n<\/ol>\n<h4><strong>Statistician \/ Biostatistician Involvement <\/strong><\/h4>\n<p style=\"text-align: justify;\">Robust trials are often designed comprehensively and methodically, with input from various experts, including a statistician. Thus, trial design should be considered in collaboration with a statistician before the development of a protocol. It is advisable that the statistician\u2019s input be sought during the following (not an exhaustive list):<\/p>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li>Designing the trial.<\/li>\n<li>Selection of appropriate outcomes.<\/li>\n<li>Justification of study sample size.<\/li>\n<li>Development of statistical plan.<\/li>\n<li>Randomisation methodology (if applicable).<\/li>\n<li>Handling of all data.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ol>\n<li style=\"text-align: justify;\">Preparation of reports to be sent to the Data Safety Monitoring Committees (if applicable) and other committees as appropriate.<\/li>\n<li>Analysis and interpretation of interim and final analyses.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">The scientific integrity of a study and the credibility of the data generated, relies heavily on its design. Therefore, it is imperative to include a biostatistician during the initial planning \/ designing phase of the study.<\/p>\n<h4><strong>References and Further reading<\/strong><\/h4>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">National Ethical Guidelines for Biomedical and Health Research involving Human Participants, Indian Council of Medical Research, 2017, available <a href=\"https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/ICMR_Ethical_Guidelines_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">online<\/a> (last accessed on 26.02.2019).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Good Clinical Practices for Clinical Research in India, Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, 2001, available <a href=\"http:\/\/www.cdsco.nic.in\/html\/GCP1.html\" target=\"_blank\" rel=\"noopener noreferrer\">online<\/a> (last accessed on 26.02.2019).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">New Drugs and Clinical Trial Rules, 2019, G.S.R. 227(E), Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, available online (last accessed on 01.04.2019).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Farrugia P, Petrisor B.A, Farrokhyar F, Bhandari M, 2010, Research questions, hypothesis and objectives, Canadian Journal of Surgery, 53, 4 pages 278 \u2013 81. [<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2912019\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed Link<\/a> \u2013 last accessed 27.09.2018].<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Doody O, Bailey ME, 2016, Setting a research question, aim and objective, Nurse Researcher, vol. 23 (4), 19 \u2013 23. [<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26997231\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed Link<\/a> \u2013 last accessed 27.09.2018].<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Lipowski EE, 2008, Developing great research questions, American Journal of Health-System Pharmacy, vol. 65 (17), 1667-70, [<a href=\"https:\/\/academic.oup.com\/ajhp\/article\/65\/17\/1667\/5128061\" target=\"_blank\" rel=\"noopener noreferrer\">available online<\/a> &#8211; last accessed on 27.09.2018].<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Onwuegbuzie A.J., Leech N.L, 2006, Linking Research Questions to Mixed Methods Data Analysis Procedures 1, The Qualitative Report, vol. 11 (3), 474-498. [<a href=\"https:\/\/scholar.google.com\/scholar?q=Onwuegbuzie%20AJ,%20Leech%20NL%20(2006)%20Linking%20research%20questions%20to%20mixed%20methods%20data%20analysis%20procedures.%20Qualitative%20Report.%2011,%203,%20474-498.\" target=\"_blank\" rel=\"noopener noreferrer\">Google Scholar Link<\/a> \u2013 last accessed on 27.09.2018].<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\">Lieberman, J.A., 2001, Hypothesis and hypothesis testing in the clinical trial, The Journal of Clinical Psychiatry, vol. 62, suppl. 9, pages 5-8, available <a href=\"https:\/\/www.psychiatrist.com\/jcp\/article\/Pages\/2001\/v62s09\/v62s0902.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">online<\/a> (last accessed 15.03.2019).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify;\">Freedman, B., 1987, Equipoise and the ethics of clinical research, New England Journal of Medicine, vol. 317 (3), pages 141-5, available <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3600702\/\" target=\"_blank\" rel=\"noopener noreferrer\">online<\/a> (last accessed 15.03.2019).<\/li>\n<\/ul>\n<\/div><\/section><\/div><div class=\"flex_column av_one_third  flex_column_div   \" style='padding:2px 0px 0px 14px ; border-radius:0px; '><div class='avia-builder-widget-area clearfix '><div id=\"custom_html-3\" class=\"widget_text widget clearfix widget_custom_html\"><h3 class=\"widgettitle\">Key Components<\/h3><div class=\"textwidget custom-html-widget\"><div class=\"hjubv\">\r\n\t\r\n\r\n<ol style=\"margin-left: 15px !important;\">\r\n\t<li><a href=\"\/?page_id=1075\" style=\"color: #000;\">Trial Planning<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=319\" style=\"color: #000;\">Trial Design<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=309\" style=\"color: red;\">Sponsorship<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=333\" style=\"color: red;\">Funding<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=339\" style=\"color: #000;\">Internationally Funded Trials<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=862\" style=\"color: #000;\">Trial Set-Up<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=343\" style=\"color: red;\">Protocol Development<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=345\" style=\"color: red;\">Essential Documents<\/a><\/li>\r\n<\/ol>\t\r\n<p class=\"kaw\">\r\n<ul style=\"margin-top: -23px;\">\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=873\" style=\"color: red;\">Case Record Form<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=877\" style=\"color: red;\">Informed Consent Documents<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=880\" style=\"color: red;\">Investigator\u2019s Brochure<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=885\" style=\"color: #000;\">Trial Master File<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=363\" style=\"color: #000;\">Laboratory Related Documents<\/a><\/li>\r\n<\/ul>\r\n<\/p>\r\n<ol start=\"9\" style=\"margin-left: 15px !important;\">\r\n\t<li><a href=\"\/?page_id=419\" style=\"color: #000;\">Risk Management<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=372\" style=\"color: #000;\">Quality and Process Management<\/a><\/li>\r\n<\/ol>\t\r\n<p class=\"kaw\">\r\n<ul style=\"margin-top: -23px;\">\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=374\" style=\"color: #000;\">Sponsor Specific Processes and Documents<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=376\" style=\"color: #000;\">Pharmacovigilance Plan<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=378\" style=\"color: #000;\">Monitoring Plan<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=962\" style=\"color: #000;\">Safety Management Plan<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=384\" style=\"color: #000;\">Randomisation System Development and User Acceptance Testing<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=386\" style=\"color: #000;\">Database Design, Development and User Acceptance Testing<\/a> <\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=355\" style=\"color: #000;\">Statistical Analysis Plan<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=380\" style=\"color: #000;\">Data Management Plan<\/a> <\/li>\r\n<\/ul>\r\n<\/p>\r\n<ol start=\"11\" style=\"margin-left: 15px !important;\">\r\n\t<li><a href=\"\/?page_id=399\" style=\"color: #000;\">Site Feasibility and Selection<\/a><\/li>\r\n<\/ol>\t\r\n<p class=\"kaw\">\r\n<ul style=\"margin-top: -23px;\">\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=401\" style=\"color: #000;\">Site Identification and Evaluation<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=382\" style=\"color: #000;\">Site-specific Processes and Documents<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=906\" style=\"color: red;\">Clinical Trial Agreement and Investigator\u2019s Undertaking<\/a><\/li>\r\n\t<li style=\"color:#7a7a7a !important\"><a href=\"\/?page_id=409\" style=\"color: #000;\">Site Staff Training<\/a><\/li>\r\n<\/ul>\r\n<\/p>\r\n<ol start=\"12\" style=\"margin-left: 15px !important;\">\r\n\t<li><a href=\"\/?page_id=812\" style=\"color: #000;\">Trial Drug Supplies<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=815\" style=\"color: #000;\">Approvals and Registration<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=421\" style=\"color: red;\">Regulatory Approval<\/a><\/li>\r\n    <li style=\"color:red !important\"><a href=\"\/?page_id=425\" style=\"color: red;\">Ethics Approval<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=852\" style=\"color: red;\">Clinical Trial Registration<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=423\" style=\"color: #000;\">Other Approvals<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=433\" style=\"color: red;\">Final Protocol<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=836\" style=\"color: #000;\">Management and Oversight Groups<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=439\" style=\"color: #000;\">Trial Begins<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=453\" style=\"color: #000;\">Trial Conduct<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=498\" style=\"color: #000;\">Trial Close-Out<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=518\" style=\"color: #000;\">Statistical Analysis and Reports<\/a><\/li>\r\n\t<li><a href=\"\/?page_id=510\" style=\"color: #000;\">Communication and Dissemination of Results<\/a><\/li>\r\n\t<li style=\"color:red !important\"><a href=\"\/?page_id=522\" style=\"color: red;\">Archiving<\/a><\/li>\r\n<\/ol>\r\n\t<\/div><\/div><\/div><div id=\"search-4\" class=\"widget clearfix widget_search\"><h3 class=\"widgettitle\">Search<\/h3>\n\n<form action=\"https:\/\/cdsatoolkit.thsti.in\/\" id=\"searchform\" method=\"get\" class=\"\">\n\t<div>\n\t\t<input type=\"submit\" value=\"\ue803\" id=\"searchsubmit\" class=\"button avia-font-entypo-fontello\" \/>\n\t\t<input type=\"text\" id=\"s\" name=\"s\" value=\"\" placeholder='Search' \/>\n\t\t\t<\/div>\n<\/form><\/div><\/div><\/div><\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='after_section_3' class='main_color av_default_container_wrap container_wrap sidebar_right'   ><div class='container' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-319'><div class='entry-content-wrapper clearfix'>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/pages\/319"}],"collection":[{"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=319"}],"version-history":[{"count":83,"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/pages\/319\/revisions"}],"predecessor-version":[{"id":3277,"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=\/wp\/v2\/pages\/319\/revisions\/3277"}],"wp:attachment":[{"href":"https:\/\/cdsatoolkit.thsti.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}